Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or volume commitments; actual business may be low or zero.
The open-house agreements automatically cease if a competitive discount agreement for the same active substance is conc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Non-exclusive discount agreements for pharmaceutical products containing Dexamethason and Gentamicin (ATC S01CA21) with AOK Bayern.
- Agreements are identical for all participants, not individually negotiated.
Show full summary
This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive pharmaceutical discount agreements (Rabattverträge) for the active substance combination Dexamethason and Gentamicin (ATC S01CA21). Any eligible pharmaceutical company can enter into identical, non-negotiable agreements. The agreement period is from May 1, 2025 to April 30, 2027. No estimated contract value is provided.
Risks
No estimated value or volume commitments; actual business may be low or zero.
The open-house agreements automatically cease if a competitive discount agreement for the same active substance is conc...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible to participate.
Administrative
- Must submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission via paper (two original copies) or electronically with qualified electronic signature (QES).
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21
Non-exclusive discount agreements for Dexamethason and Gentamicin (ATC S01CA21). Eligible pharmaceutical companies can join the open-house model at any time until March 5, 2027. Agreements run from May 1, 2025 to April 30, 2027.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 18 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 176568-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or volume commitments; actual business may be low or zero.
The open-house agreements automatically cease if a competitive discount agreement for the same active substance is conc...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications